Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chattopadhyay, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chattopadhyay, B.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 13-16
© 2002 The British Society for Antimicrobial Chemotherapy


Leading articles

Newborns and gentamicin—how much and how often?

B. Chattopadhyay,*

Medical Microbiology Department, Whipps Cross University Hospital NHS Trust, Leytonstone, London E11 1NR, UK

Aminoglycosides are widely used in the treatment of suspected or proven severe bacterial infections. Combined with ß-lactam antibiotics, gentamicin provides synergic activity against the most commonly encountered pathogens in the first month of life, including the frequently isolated coagulase-negative staphylococci. The clinical use of aminoglycosides is limited, unfortunately, by their potential ototoxicity and nephrotoxicity.1 Nevertheless, their concentration-dependent bactericidal action and post-antibiotic effect, antibacterial synergy with ß-lactams and low cost, and the better understanding of risk factors associated with the use of these agents, are favourable points for their continued use. The risk of aminoglycoside-induced nephrotoxicity and ototoxicity, although controversial in newborns, must still be considered a potential hazard related to drug accumulation.2–4 Until substantial evidence proves otherwise, maintaining serum gentamicin concentrations within the accepted therapeutic range in newborns continues to be prudent.

In order to obtain optimal therapeutic effect and to prevent potential toxicity associated with high post-dose and pre-dose . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Antimicrob ChemotherHome page
B. Garcia, E. Barcia, F. Perez, and I. T. Molina
Population pharmacokinetics of gentamicin in premature newborns
J. Antimicrob. Chemother., August 1, 2006; 58(2): 372 - 379.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
J. M. Lanao, M. V. Calvo, J. A. Mesa, A. Martin-Suarez, M. T. Carbajosa, F. Miguelez, and A. Dominguez-Gil
Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates
J. Antimicrob. Chemother., July 1, 2004; 54(1): 193 - 198.
[Abstract] [Full Text] [PDF]